SEC Form 4 · accession 0001140361-17-012602
Loxo Oncology, Inc. · LOXO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joshua H. Bilenker
Officer — President & CEO · Director
Period of report
Mar 15, 2017
Accepted (ET)
Mar 17, 2017 · 5:10 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001581720
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $43.56 | Mar 15, 2017 | A | 100,000 | A | — | Mar 14, 2027 | Common Stock | 100,000 | 100,000 | D |
Explanation of responses
- F1The stock option vests and becomes exercisable in 48 equal monthly installments beginning one month after the grant date, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.